Page 5 - தேவெ ரோஜர்சன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேவெ ரோஜர்சன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேவெ ரோஜர்சன் Today - Breaking & Trending Today

Enesi Pharma's ImplaVax®-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

Share this article
Share this article
OXFORD, England, May 6, 2021 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical swine fever (CSF) vaccine.
The results showed that a novel solid-dose ImplaVax® formulation of a recombinant E2 antigen CSF virus vaccine delivered subcutaneously using the ImplaVax® needle-free injection device generated a stronger immune response than standard liquid CSF vaccine formulations, particularly in terms of CSF virus-specific T-cell responses. ....

United Kingdom , Prnewswire Enesi Pharma , Enesi Pharma , David Hipkiss , Nathaniel Dahan , Citigate Dewe Rogerson , Walter Reed Army Institute Of Research , University Of Oxford , Biomedical Advanced Research , Human Services , Pirbright Institute , Melinda Gates Foundation , Development Authority , Department Of Health , University Of Adelaide , Office Of The , Virus Research , Porcine Reproductive , Respiratory Syndrome , Innovate United Kingdom , Walter Reed Army Institute , Scientific Advisory , Assistant Secretary , Dewe Rogerson , ஒன்றுபட்டது கிஂக்டம் , நத்யாநியல் தஹான் ,

Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella

Share this article
Share this article
OXFORD, England, May 5, 2021 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. The project, which started in October 2019, received funding from the Bill & Melinda Gates Foundation.
The project established important proof-of-concept for ImplaVax®-enabled unit solid-dose presentations of both vaccines, demonstrating that each was thermally stable at temperatures of 40°C for three days and at 25°C for at least one month, and met key criteria for retained activity. Further longer-term stability studies are underway, and the Company is planning the immunogenicity studies needed to determine ....

United Kingdom , Prnewswire Enesi Pharma , Enesi Pharma , David Hipkiss , Nathaniel Dahan , Citigate Dewe Rogerson , Walter Reed Army Institute Of Research , University Of Oxford , Biomedical Advanced Research , Human Services , Pirbright Institute , World Health Organization , Melinda Gates Foundation , Development Authority , Department Of Health , University Of Adelaide , Office Of The , Melinda Gates , World Health , Innovate United Kingdom , Walter Reed Army Institute , Scientific Advisory , Assistant Secretary , Dewe Rogerson , ஒன்றுபட்டது கிஂக்டம் , நத்யாநியல் தஹான் ,

Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

Share this article
Share this article
OXFORD, England, May 4, 2021 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax
® technologies, announces that it has successfully developed an ImplaVax®-enabled, solid-dose recombinant H7N9 pandemic influenza vaccine and delivered proof-of-concept results in validated preclinical models.
The project
1 was conducted as part of BARDA s
Beyond the Needle initiative, which is focused on developing alternative technologies that aim to transform the paradigm of making vaccines and therapeutics easier to administer and more widely available, without the need for needles, syringes, vials, and cold-chain distribution burdens. ....

United Kingdom , Prnewswire Enesi Pharma , Enesi Pharma , Enesi Implavax , David Hipkiss , Nathaniel Dahan , Citigate Dewe Rogerson , Walter Reed Army Institute Of Research , Us National Strategic , University Of Oxford , Us Department Of Health , Human Services , Biomedical Advanced Research , Pirbright Institute , Melinda Gates Foundation , Development Authority , World Vaccine Congress , Department Of Health , University Of Adelaide , Office Of The , Plant Agency , Barda Drive Team , Assistant Secretary , Innovate United Kingdom , Walter Reed Army Institute , Scientific Advisory ,

Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Prnewswire Enesi Pharma , Enesi Pharma , Enesi Implavax , David Hipkiss , Nathaniel Dahan , Citigate Dewe Rogerson , Walter Reed Army Institute Of Research , Us National Strategic , University Of Oxford , Us Department Of Health , Human Services , Biomedical Advanced Research , Pirbright Institute , Melinda Gates Foundation , Development Authority , World Vaccine Congress , Department Of Health , University Of Adelaide , Office Of The , Plant Agency , Barda Drive Team , Assistant Secretary , Innovate United Kingdom , Walter Reed Army Institute , Scientific Advisory ,

Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting

Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting
News provided by
Share this article
Share this article
OXFORD, England, April 27, 2021 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (WVC 2021, 4-6 May 2021), which this year is free to attend.
The presentation, entitled
Logistics, last-mile, and innovations to ensure successful deployment of next-generation COVID-19 vaccines, will also look at the development and application of Enesi s needle-free, unit solid-dose, thermally stable ImplaVax® platform and how it is enabling a number of vaccines of potential global significance. The presentation will take place at 14:30 EST on Thursday 6 ....

United Kingdom , Enesi Pharma , Enesi Implavax , David Hipkiss , Nathaniel Dahan , Citigate Dewe Rogerson , Walter Reed Army Institute Of Research , University Of Oxford , Biomedical Advanced Research , Human Services , Pirbright Institute , Melinda Gates Foundation , Development Authority , World Vaccine Congress , Plant Health Agency , Department Of Health , University Of Adelaide , Office Of The , Innovate United Kingdom , Walter Reed Army Institute , Scientific Advisory , Assistant Secretary , Dewe Rogerson , ஒன்றுபட்டது கிஂக்டம் , நத்யாநியல் தஹான் , வால்டர் நாணல் இராணுவம் நிறுவனம் ஆஃப் ஆராய்ச்சி ,